Recent studies have demonstrated that C-peptide exerts beneficial effects on endothelial function. To investigate the relationship between residual pancreatic C-peptide secretion and endothelial function in patients with well controlled or poorly controlled Type II diabetes, we studied 100 patients with Type II diabetes that were free from diabetic neuropathy. In all patients, insulin resistance, residual pancreatic C-peptide secretion, endothelial function and oxidative stress were investigated using the homoeostasis model assessment (HOMA) index, glucagon bolus test, brachial reactivity, Trolox equivalent antioxidant capacity (TEAC) and thiobarbituric acidreacting substances (TBARS). The patients were categorized into quartiles on the basis of plasma HbA 1c (glycated haemoglobin) concentration. Analysis of the data showed significant increases in plasma glucose concentration, HOMA index, microalbuminuria and TBARS, and significant decreases in plasma C-peptide, AUC (area under the curve) plasma C-peptide and TEAC, through the different quartiles (from the lowest to the highest HbA 1c concentration). With regard to parameters of endothelial function, changes in diameter showed a significant declining trend through the different quartiles. Endothelial-dependent changes in diameter were independently and significantly associated with AUC C-peptide levels, TEAC and TBARS. In conclusion, our study demonstrated that patients with Type II diabetes with good residual C-peptide secretion are better protected from endothelial dysfunction that those with poor C-peptide secretion.
INTRODUCTION
Numerous studies have shown the occurrence of endothelial dysfunction in patients with diabetes [1, 2] . Despite the fact that the sequential events involved in endothelial dysfunction are well known [3, 4] , our knowledge of the pathophysiological mechanisms underlying the relationship between diabetes mellitus and endothelial dysfunction is incomplete.
Previous studies have demonstrated that the systemic administration of C-peptide improves vascular, neural [5] and renal [6] dysfunction in diabetic rats, and decreases glomerular filtration and increases renal plasma flow in patients with Type I diabetes [7, 8] . In addition, it has been shown that C-peptide promotes arteriolar dilatation in skeletal muscle [9] by a nitric oxide-mediated mechanism. Indeed, there is increasing evidence that residual C-peptide secretion in patients with Type 1 diabetes is associated with, in addition to tight glucose metabolic control, a reduced appearance of microvascular complications [10, 11] .
In light of this experimental evidence, it is possible to hypothesize that patients with Type II diabetes who have good residual C-peptide secretion would have better preserved endothelial function than patients with poor metabolic control and poor residual C-peptide secretion. To the best of our knowledge, no study has addressed such a hypothesis in Type II diabetic patients. Thus our present study investigates the impact of residual pancreatic C-peptide secretion on endothelial function in patients with well controlled or poorly controlled Type II diabetes, independent of the degree of insulin resistance.
METHODS

Subjects
A total of 100 outpatients with Type II diabetes volunteered for the study; patient details are given in Table 1 . All subjects were treated with glibenclamide (2.5 mg) plus metformin (400 mg) twice daily. The presence of diabetic neuropathy was excluded in all patients by clinical investigation and Ewing's test [12] . No patients had evidence of coronary heart disease (as demonstrated by a treadmill test). In all patients, insulin resistance and residual pancreatic β-cell function were investigated by the homoeostasis model assessment (HOMA) index [13] and the glucagon bolus test [14, 15] respectively. Endothelial-dependent and -independent vasodilatation was measured in order to investigate endothelial function. All subjects gave informed consent to participate in the study, which was approved by the Ethical Committee of our institution. 
Experimental design
The study was performed in a comfortable room with a temperature ranging between 22 and 24 • C. After an overnight fast (at least 12 h), a venous blood sample was drawn immediately from each patient for plasma metabolite determinations. Subsequently, in a random order and on different days, each subject was subjected to a glucagon test and a brachial reactivity study.
Anthropometric determinations
Weight and height were measured using standard techniques. Body mass index (BMI) was calculated as body weight (kg)/height (m 2 ). Waist circumference was measured at the midpoint between the lower rib margin and the iliac crest (normally at the umbilical level), and hip circumference at the level of the throcanter. Both circumferences were measured to the nearest 5 mm with a plastic tape, and the waist/hip ratio was calculated.
Glucagon test
The glucagon test consists of one intravenous bolus injection of glucagon (1 mg; Novo-Nordisk Industri, Copenhagen, Denmark). The area under the curve (AUC) of plasma C-peptide was used as an index of endogenous residual β-cell function [16] .
HOMA index
Insulin resistance was assessed by the HOMA index [13] . HOMA is a mathematical model describing the degree of insulin resistance, starting from patient's fasting plasma insulin and glucose concentrations [13] . The accuracy and precision of the HOMA method have been compared with independent estimates of insulin resistance [13] .
Endothelial function
Endothelial function was evaluated by a brachial reactivity study. Brachial reactivity was detected using a high-frequency ultrasound technique, and differences between endothelial-dependent and endothelialindependent vasodilatation were assessed by evaluating brachial reactivity parameters after nitroglycerine (NTG; 0.4 mg, sublingual), as reported elsewhere [17, 18] . Briefly, all patients rested in a supine position in a temperaturecontrolled room (22 • C) while heart rate and blood pressure were monitored continuously by a non-invasive technique (Finapress) [19] . The left arm was immobilized in the extended position to allow consistent access to the brachial artery for imaging. Brachial artery diameter and flow velocity were imaged using a 7.5 MHz linear array transducer ultrasound system (Apogee CX; Interspec ATL, Ambler, PA, U.S.A.). Brachial arterial diameter and blood flow velocity were recorded at intervals of 1 min. Then a blood pressure cuff was placed over the ipsilateral upper arm just above the transducer, and inflated for 5 min at 200 mmHg and then suddenly deflated. The post-ischaemic scan was performed 60 s after cuff deflation, while brachial artery diameter and flow were measured at 1 min intervals for 5 min. All images were recorded on videotape for subsequent offline analysis on the same instrument by a single observer blinded to the conditions under which the ultrasonic images were obtained.
Intra-observer variability for the measurement of brachial artery diameter and flow was assessed by comparing a minimum of three separate baseline measurements for each patient. The coefficient of variation for baseline arterial diameter was 2.1 %, and that for baseline arterial flow was 9.7 %. These values were not dissimilar from those reported by other authors [20] .
Analytical techniques
Plasma glucose concentration was determined by the glucose oxidative method (glucose autoanalyser; Beckman Coulter Inc., Fullerton, CA, U.S.A.). Plasma levels of C-peptide (Sorin Biomedical, Milan, Italy; coefficient of variation 3.9 + − 0.4 %) and insulin (Linco Research Inc., St Charles, MO, U.S.A.; coefficient of variation, 4.8 + − 0.3 %; cross-reactivity with proinsulin, 0.2 %) were determined by RIA methods. Stable HbA 1c (glycated haemoglobin) levels were determined in triplicate according to the method of Compagnucci et al. [21] on ion-exchange microcolumns at constant temperature (18 • C). Microalbuminuria was determined by routine laboratory methods (normal values 20 µg/min). The degree of serum oxidative stress was measured as the reaction products of malondialdehyde with thiobarbituric acid (thiobarbituric acid-reacting substances; TBARS) [22] [23] [24] ; the inter-and intraassay coefficients of variation were 3.4 % and 2.3 % respectively. Plasma total antioxidant capacity, as Trolox equivalent antioxidant capacity (TEAC), was estimated by the 2,2-azinobis-3-ethylbenzothiazoline-6-sulphonic acid radical cation decolorization assay, using Trolox as a standard, according to the method of Pellegrini et al. [25] ; the inter-and intra-assay coefficients of variation were 5.2 % and 3.8 % respectively.
Calculations and statistical analysis
All data are presented as means + − S.D. Mean arterial blood pressure (MABP) was calculated as diastolic blood pressure plus one-third pulse pressure. AUC for glucagon-induced C-peptide secretion was calculated using the trapezoidal rule. Data for brachial artery diameter and flow are expressed as percentage change from baseline values, calculated as the maximal change within the interval of observation. To approximate a normal distribution, basal plasma C-peptide levels, AUC C-peptide and HOMA index were log-transformed (for all calculations) and then back-transformed (for presentation of results). ANOVA was used to assess differences among the HbA 1c groups organized in quartiles. When P < 0.05, Scheffé's test was also performed. ANOVA for repeated measures was used for calculating the P values for the trend for each variable among the different groups. Multivariate linear regression analyses were used to test for the independent association of endothelial-dependent changes in diameter with gender, age, BMI, MABP, microalbuminuria, TEAC, TBARS, HOMA and AUC C-peptide. All calculations were performed on a PC with SPSS 10 (SPSS Inc., Chicago, IL, U.S.A.).
RESULTS
Metabolic and oxidative parameters, stratified into quartiles on the basis of plasma HbA 1c concentration, are reported in Table 2 . Analysis of data showed similar values among the quartiles for gender, age, BMI, waist/hip ratio and MABP. In contrast, significant increases in plasma glucose concentration, HOMA index, microalbuminuria and TBARS were found through the different quartiles, from the lowest to the highest value of plasma HbA 1c . In contrast, plasma C-peptide concentration, AUC plasma C-peptide and plasma TEAC concentration showed decreasing trends.
With regard to endothelial function parameters (Table 3) , changes in diameter (both with and without NTG) showed significant declining trends over the quartiles (lowest in the quartile with the highest plasma HbA 1c concentration), whereas there were no significant differences among the quartiles with regard to changes in flow (both with and without NTG). To investigate the relationship between the change in brachial artery diameter and the HOMA index or AUC C-peptide, a correlation analysis was performed. Endothelialdependent changes in diameter were correlated significantly with both HOMA index (r = − 0.25; P < 0.01) and AUC C-peptide (r = 0.28; P < 0.01). In contrast, no significant correlations were found between NTGmediated changes in arterial diameter and AUC Cpeptide (r = − 0.16) or HOMA index (r = 0.14).
To confirm an independent association of endothelialdependent changes in diameter and AUC C-peptide, a multivariate analysis was also performed (Table 4) . In this analysis, the endothelial-dependent change in diameter was the dependent variable, while gender, age, BMI, MABP, microalbuminuria, TEAC, TBARS, HOMA and AUC C-peptide were the independent variables. This model explained 56 % of the variability in endothelialdependent changes in diameter. AUC C-peptide (P < 0.001), TEAC (P < 0.04) and TBARS (P < 0.003) were independently and significantly associated with variability in endothelial-dependent changes in diameter (Table 4) . 
DISCUSSION
Our study demonstrates that patients with Type II diabetes who show a progressive decrease in residual C-peptide secretion have increasingly poor endothelial function. The vascular endothelium regulates blood flow by tightly controlling the coagulation system, cell-cell interactions and vascular tone [26] . These functions are impaired in diabetic patients, whose endothelial-cell/NO axis is disturbed by impaired NO release and function [26, 27] . Indeed, it has been demonstrated that diabetic complications, such as retinopathy, nephropathy and neuropathy, as well as accelerated atherosclerosis, are preceded by the development of endothelial dysfunction [26] . This suggests that diabetic complications may be overcome by the prevention of endothelial dysfunction. Unfortunately, the specific factor(s) involved in the prevention of endothelial dysfunction in diabetes have not yet been identified. It is postulated that plasma C-peptide levels might play an important role in the prevention of endothelial dysfunction. The cellular mechanisms that form the basis of the vascular effects of C-peptide are still under investigation. Preliminary evidence shows that C-peptide, via an increase in the intracellular Ca 2+ concentration, stimulates endothelial NO synthase activity [28, 29] . This hypothesis is supported by a study [28] showing that C-peptide activates endothelial NO secretion in a calcium-dependent fashion in Type II diabetic patients, an effect that was completely abolished by l-nitro-arginine, a specific inhibitor of endothelial NO synthase. Moreover, C-peptide has also been shown to stimulate Na + ,K + -ATPase activity in a dosedependent manner in renal tubular cells [6] . This is particularly significant in the light of evidence that, in diabetic patients, Na + ,K + -ATPase activity is decreased in various cell types, and might be involved in the pathogenesis of various diabetic complications [30] [31] [32] [33] . Indeed, studies have also demonstrated that injection of human C-peptide improves Na + ,K + -ATPase activity in the tissues of diabetic rats [5] . In addition, a positive linear relationship exists between residual plasma C-peptide levels and erythrocyte Na + ,K + -ATPase activity in patients with Type II diabetes [34] . In agreement with the above findings, C-peptide has been shown to be involved in the concentration-dependent dilatation of rat skeletal muscle arterioles, a phenomenon occurring via an NO-mediated mechanism [9] .
To the best of our knowledge, our present study provides the first evidence documenting an association between good residual C-peptide secretion and preserved endothelial function in patients with Type II diabetes. Despite the fact that our study had a cross-sectional design, which did not allow us to draw a cause-effect conclusion, the relationship between good residual Cpeptide secretion and preserved endothelial function was supported by the existence of a significant association between brachial arterial diameter related to endothelialdependent vasodilatation and AUC C-peptide levels, which was independent of gender, age, BMI, MABP, microalbuminuria and HOMA. This might be the result of less severe structural and functional endothelial damage in Type II diabetic patients with good residual C-peptide secretion. Such data are in agreement with and support studies showing high plasma C-peptide levels to be associated with slower progression of microvascular complications in patients with Type I diabetes [35] [36] [37] [38] . In fact, C-peptide administration in Type I diabetic patients is associated with: (i) increased blood flow in skeleta1 muscle both at rest [35] and during exercise [36] ; (ii) augmented capillary blood cell velocity [37] ; and (iii) redistribution of skin microvascular blood flow [35, 37, 38] . Indeed, the finding that administration of human C-peptide prevents decreased Na + ,K + -ATPase activity in rat sciatic nerve [5] , granulation tissue [5] and red blood cells [39] also suggests that high C-peptide levels are required for the prevention of vascular dysfunction associated with the occurrence of diabetes mellitus. In addition, our present study indicates that the existence of significant associations between brachial arterial diameter related to endothelialdependent vasodilatation and indices of oxidative stress (TEAC and TBARS) underlies preserved endothelial function in diabetic patients with a good residual C-peptide secretion in association with a slight degree of oxidative stress. Thus one may conclude that oxidative stress and preserved pancreas secretion may have independent impacts on endothelial function.
A potential confounding factor of our study might be plasma insulin values, since insulin and C-peptide are secreted in an equimolar fashion. Indeed, insulin mainly has a vasodilatory effect, and thus one could argue that the apparent effects of C-peptide are largely due to insulin. Nevertheless, one should differentiate between the effects of insulin in non-diabetic subjects compared with those in diabetic patients, who are also affected by insulin resistance. In this latter group of patients, hyperinsulinaemia, which represents an effort to offset the degree of insulin resistance, contributes to the deterioration of endothelial function. Thus endothelial function in diabetic patients would be exposed to both hyperinsulinaemia/insulin resistance and plasma C-peptide concentrations, which may have contrasting effects on endothelium function. We took such a possibility into account, since we showed that the HOMA index was negatively correlated with endothelial-dependent changes, while the multivariate analysis demonstrated that only AUC C-peptide levels, TEAC and TBARS were independently and significantly associated with endothelial-dependent changes in diameter.
Our present finding opens up potential new therapeutic options in therapy for patients with Type II diabetes. In particular, additional studies will be required to elucidate further the possibility of C-peptide administration for the prevention and treatment of macrovascular complications in diabetes.
